Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 1/2 1

Status

Completed 9Withdrawn 3Recruiting 2Unknown 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 3Other hematologic neoplasm 3Thoracic 1Myeloid 1Genitourinary 1Breast 1

Conditions

Multiple Myeloma 3

Interventions

Dexamethasone 48Calcium Dobesilate 20Bortezomib 20Lenalidomide 19Melphalan 16daratumumab 11Cyclophosphamide 11pomalidomide 10elotuzumab 8carfilzomib 8dexamethasone acetate 7pembrolizumab 6ixazomib 6fludarabine phosphate 6dexamethasone 21-phosphate 6venetoclax 5selinexor 5fludarabine 5auricularum 5Filgrastim 5liposomal doxorubicin 4Thalidomide 4Tacrolimus 4Peripheral Blood Stem Cell Transplantation 4Magnetic Resonance Spectroscopy 4Whole-Body Irradiation 3Vorinostat 3Simvastatin 3Nivolumab 3Mycophenolic Acid 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Withdrawn × Leukapheresis × Plasma cell × Clear all
NCT05950113 2024-05-01

CART-BCMA/CS1 in Treating Patients With Relapsed or Refractory Multiple Myeloma

Jonsson Comprehensive Cancer Center

Phase 1 Withdrawn
Plasma cell

Multiple Myeloma

NCT03506802 2020-07-24

NYSCT MM

Jonsson Comprehensive Cancer Center

Phase 1 Withdrawn
Plasma cell

Multiple Myeloma

NCT03100877 2017-12-13

Melphalan, Total Marrow Irradiation, and Autologous Stem Cell Transplantation in Treating Patients With High-Risk Multiple Myeloma

City of Hope Medical Center

Phase 1/2 Withdrawn
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡